Primary angioplasty in myocardial infarction: Assessment of improved myocardial perfusion with technetium-99m isonitrile

T. Behrenbeck, Patricia Pellikka, K. C. Huber, J. F. Bresnahan, B. J. Gersh, Raymond J Gibbons

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Technetium-99m-hexakis-2-methoxy-2-isobutyl-isonitrile (technetium-99m isonitrile) is a new radiopharmaceutical compound that reflects myocardial perfusion. Its kinetics, especially its lack of redistribution after intravenous administration, permits the assessment of changes in myocardial perfusion without delay of therapy. Tomographic images at rest were obtained immediately and 6 to 10 days later in 17 consecutive patients undergoing successful primary angioplasty during their first transmural myocardial infarction. Thirteen patients had anterior infarction. The initial (acute) defect size before angioplastv of 48 ± 17% of the left ventricle decreased significantly (p < 0.0001) to 29 ± 19% on the late scans. There was no correlation between the time to therapy and the reduction in defect size. Twelve of the 17 patients, including 7 of the 11 patients treated after 4 h, demonstrated a definite reduction in the initial defect size. Eight patients with angiographically proved persistent coronary occlusion underwent a similar imaging sequence. The initial defect size in this group remained unchanged on the late scans (24 ± 16% versus 26 ± 18%, p = NS). Primary angioplasty is an effective approach toward salvaging myocardium; comparison with thrombolytic drug therapy must await the results of controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalJournal of the American College of Cardiology
Volume17
Issue number2
StatePublished - 1991

Fingerprint

Technetium
Angioplasty
Perfusion
Myocardial Infarction
Fibrinolytic Agents
Radiopharmaceuticals
Coronary Occlusion
Thrombolytic Therapy
Controlled Clinical Trials
Intravenous Administration
Infarction
Heart Ventricles
Myocardium
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Primary angioplasty in myocardial infarction : Assessment of improved myocardial perfusion with technetium-99m isonitrile. / Behrenbeck, T.; Pellikka, Patricia; Huber, K. C.; Bresnahan, J. F.; Gersh, B. J.; Gibbons, Raymond J.

In: Journal of the American College of Cardiology, Vol. 17, No. 2, 1991, p. 365-372.

Research output: Contribution to journalArticle

@article{5a726a1dc4754933b19e45892820edf8,
title = "Primary angioplasty in myocardial infarction: Assessment of improved myocardial perfusion with technetium-99m isonitrile",
abstract = "Technetium-99m-hexakis-2-methoxy-2-isobutyl-isonitrile (technetium-99m isonitrile) is a new radiopharmaceutical compound that reflects myocardial perfusion. Its kinetics, especially its lack of redistribution after intravenous administration, permits the assessment of changes in myocardial perfusion without delay of therapy. Tomographic images at rest were obtained immediately and 6 to 10 days later in 17 consecutive patients undergoing successful primary angioplasty during their first transmural myocardial infarction. Thirteen patients had anterior infarction. The initial (acute) defect size before angioplastv of 48 ± 17{\%} of the left ventricle decreased significantly (p < 0.0001) to 29 ± 19{\%} on the late scans. There was no correlation between the time to therapy and the reduction in defect size. Twelve of the 17 patients, including 7 of the 11 patients treated after 4 h, demonstrated a definite reduction in the initial defect size. Eight patients with angiographically proved persistent coronary occlusion underwent a similar imaging sequence. The initial defect size in this group remained unchanged on the late scans (24 ± 16{\%} versus 26 ± 18{\%}, p = NS). Primary angioplasty is an effective approach toward salvaging myocardium; comparison with thrombolytic drug therapy must await the results of controlled clinical trials.",
author = "T. Behrenbeck and Patricia Pellikka and Huber, {K. C.} and Bresnahan, {J. F.} and Gersh, {B. J.} and Gibbons, {Raymond J}",
year = "1991",
language = "English (US)",
volume = "17",
pages = "365--372",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Primary angioplasty in myocardial infarction

T2 - Assessment of improved myocardial perfusion with technetium-99m isonitrile

AU - Behrenbeck, T.

AU - Pellikka, Patricia

AU - Huber, K. C.

AU - Bresnahan, J. F.

AU - Gersh, B. J.

AU - Gibbons, Raymond J

PY - 1991

Y1 - 1991

N2 - Technetium-99m-hexakis-2-methoxy-2-isobutyl-isonitrile (technetium-99m isonitrile) is a new radiopharmaceutical compound that reflects myocardial perfusion. Its kinetics, especially its lack of redistribution after intravenous administration, permits the assessment of changes in myocardial perfusion without delay of therapy. Tomographic images at rest were obtained immediately and 6 to 10 days later in 17 consecutive patients undergoing successful primary angioplasty during their first transmural myocardial infarction. Thirteen patients had anterior infarction. The initial (acute) defect size before angioplastv of 48 ± 17% of the left ventricle decreased significantly (p < 0.0001) to 29 ± 19% on the late scans. There was no correlation between the time to therapy and the reduction in defect size. Twelve of the 17 patients, including 7 of the 11 patients treated after 4 h, demonstrated a definite reduction in the initial defect size. Eight patients with angiographically proved persistent coronary occlusion underwent a similar imaging sequence. The initial defect size in this group remained unchanged on the late scans (24 ± 16% versus 26 ± 18%, p = NS). Primary angioplasty is an effective approach toward salvaging myocardium; comparison with thrombolytic drug therapy must await the results of controlled clinical trials.

AB - Technetium-99m-hexakis-2-methoxy-2-isobutyl-isonitrile (technetium-99m isonitrile) is a new radiopharmaceutical compound that reflects myocardial perfusion. Its kinetics, especially its lack of redistribution after intravenous administration, permits the assessment of changes in myocardial perfusion without delay of therapy. Tomographic images at rest were obtained immediately and 6 to 10 days later in 17 consecutive patients undergoing successful primary angioplasty during their first transmural myocardial infarction. Thirteen patients had anterior infarction. The initial (acute) defect size before angioplastv of 48 ± 17% of the left ventricle decreased significantly (p < 0.0001) to 29 ± 19% on the late scans. There was no correlation between the time to therapy and the reduction in defect size. Twelve of the 17 patients, including 7 of the 11 patients treated after 4 h, demonstrated a definite reduction in the initial defect size. Eight patients with angiographically proved persistent coronary occlusion underwent a similar imaging sequence. The initial defect size in this group remained unchanged on the late scans (24 ± 16% versus 26 ± 18%, p = NS). Primary angioplasty is an effective approach toward salvaging myocardium; comparison with thrombolytic drug therapy must await the results of controlled clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0025763475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025763475&partnerID=8YFLogxK

M3 - Article

C2 - 1825094

AN - SCOPUS:0025763475

VL - 17

SP - 365

EP - 372

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -